IMMUNOGEONOMICS AND FLOW CYTOMETRY SHARED RESOURCE The Immunogenomics and Flow Cytometry SR (IMCF) is a hybrid core that provides access to state-of-the-art techniques such as mass cytometry and immunogenomics analysis of bulk and single cell next generation sequencing data coupled with a high utilization Flow Cytometry facility with a 30-year LCCC history. New immune monitoring capabilities were developed in response to investigator needs, particularly for the analysis of immune responses in preclinical tumor models and human clinical research. The immunogenomics component offers a full suite of immunogenomics techniques, including immune gene signature and pathway analysis, cell phenotype deconvolution, MHC haplotype prediction, neoantigen prediction, T cell and B cell repertoire profiling, and systems level analyses such as cytokine network analysis and integrated survival modeling. This is joined by an investment in CyTOF for expanded panel analysis of cellular phenotypes. This component currently supports correlative science for tissues being collected from eight immunotherapy trials and multiple in vivo animal models of cancer. In addition to these new capabilities, the facility also houses a full complement of highly used analytic flow cytometers and cell sorters for both mouse and human work, New purchases in addition the CyTOF are two new spectral analytic machines. Most important for the research community, all SR components have expert staff to support investigators in experimental design, sample processing, data acquisition, and downstream analysis. IMCF is led by Dr. Vincent, MD, an expert in immunogenomics and Dr. Fisher, PhD who has led the LCC Flow facility since 2010 and has over 30 years? experience in flow cytometry. The budget requested ($211,126) is a small proportion of the total operating budget of $1.7M. Flow cytometry is a traditionally heavily used facility; 80 members were users in fiscal year 2019.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Chapel Hill
United States
Zip Code
Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Moschos, Stergios J; Sullivan, Ryan J; Hwu, Wen-Jen et al. (2018) Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3:
Brosnan, Evelyn M; Anders, Carey K (2018) Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 6:163
Valle, Carmina G; Queen, Tara L; Martin, Barbara A et al. (2018) Optimizing Tailored Communications for Health Risk Assessment: A Randomized Factorial Experiment of the Effects of Expectancy Priming, Autonomy Support, and Exemplification. J Med Internet Res 20:e63
Sun, Junjiang; Shao, Wenwei; Chen, Xiaojing et al. (2018) An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Mol Ther Methods Clin Dev 10:257-267
Wilczewski, Caralynn M; Hepperla, Austin J; Shimbo, Takashi et al. (2018) CHD4 and the NuRD complex directly control cardiac sarcomere formation. Proc Natl Acad Sci U S A 115:6727-6732
Anderson, Chelsea; Engel, Stephanie M; Anders, Carey K et al. (2018) Live birth outcomes after adolescent and young adult breast cancer. Int J Cancer 142:1994-2002
Gralinski, Lisa E; Sheahan, Timothy P; Morrison, Thomas E et al. (2018) Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. MBio 9:
Au, Kin Man; Tripathy, Ashutosh; Lin, Carolina Pe-I et al. (2018) Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma. ACS Nano 12:1544-1563

Showing the most recent 10 out of 1525 publications